Pharmacological inhibition of the MAP2K7 kinase in human disease
The MAP2K7 signaling pathway activates the c-Jun NH2-terminal protein kinase (JNK) in response to stress signals, such as inflammatory cytokines, osmotic stress, or genomic damage. While there has been interest in inhibiting JNK due to its involvement in inflammatory processes and cancer, there is i...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1486756/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136365208567808 |
|---|---|
| author | H. Daniel Lacorazza |
| author_facet | H. Daniel Lacorazza |
| author_sort | H. Daniel Lacorazza |
| collection | DOAJ |
| description | The MAP2K7 signaling pathway activates the c-Jun NH2-terminal protein kinase (JNK) in response to stress signals, such as inflammatory cytokines, osmotic stress, or genomic damage. While there has been interest in inhibiting JNK due to its involvement in inflammatory processes and cancer, there is increasing focus on developing MAP2K7 inhibitors to enhance specificity when MAP2K7 activation is associated with disease progression. Despite some progress, further research is needed to fully comprehend the role of MAP2K7 in cancer and assess the potential use of kinase inhibitors in cancer therapy. This review examines the role of MAP2K7 in cancer and the development of small-molecule inhibitors. |
| format | Article |
| id | doaj-art-ff6e42e5dfdd4a3da9bf27b3171caab3 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ff6e42e5dfdd4a3da9bf27b3171caab32024-12-09T06:28:46ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.14867561486756Pharmacological inhibition of the MAP2K7 kinase in human diseaseH. Daniel LacorazzaThe MAP2K7 signaling pathway activates the c-Jun NH2-terminal protein kinase (JNK) in response to stress signals, such as inflammatory cytokines, osmotic stress, or genomic damage. While there has been interest in inhibiting JNK due to its involvement in inflammatory processes and cancer, there is increasing focus on developing MAP2K7 inhibitors to enhance specificity when MAP2K7 activation is associated with disease progression. Despite some progress, further research is needed to fully comprehend the role of MAP2K7 in cancer and assess the potential use of kinase inhibitors in cancer therapy. This review examines the role of MAP2K7 in cancer and the development of small-molecule inhibitors.https://www.frontiersin.org/articles/10.3389/fonc.2024.1486756/fullMAP2K7kinase inhibitorsT-ALLleukemiamitogen-activated protein kinase kinase 7cancer |
| spellingShingle | H. Daniel Lacorazza Pharmacological inhibition of the MAP2K7 kinase in human disease Frontiers in Oncology MAP2K7 kinase inhibitors T-ALL leukemia mitogen-activated protein kinase kinase 7 cancer |
| title | Pharmacological inhibition of the MAP2K7 kinase in human disease |
| title_full | Pharmacological inhibition of the MAP2K7 kinase in human disease |
| title_fullStr | Pharmacological inhibition of the MAP2K7 kinase in human disease |
| title_full_unstemmed | Pharmacological inhibition of the MAP2K7 kinase in human disease |
| title_short | Pharmacological inhibition of the MAP2K7 kinase in human disease |
| title_sort | pharmacological inhibition of the map2k7 kinase in human disease |
| topic | MAP2K7 kinase inhibitors T-ALL leukemia mitogen-activated protein kinase kinase 7 cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1486756/full |
| work_keys_str_mv | AT hdaniellacorazza pharmacologicalinhibitionofthemap2k7kinaseinhumandisease |